POLYCYTHEMIA VERA

This study tests whether ruxolitinib works better than current standard treatments (hydroxycarbamide or interferon) for people with high-risk polycythemia vera, a blood cancer that increases red blood cells. About 586 adults with high-risk disease will be randomly assigned to rux…

This study tests a new drug called sapablursen for people with polycythemia vera, a blood disorder that causes too many red blood cells. The goal is to see if adding this drug to standard care can reduce the need for phlebotomy (blood removal). About 250 adults who currently need…

This study tests a two-step approach for people with advanced myeloproliferative neoplasms (blood cancers). First, patients receive a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) to reduce cancer cells. Then, they undergo a donor…

This study tests whether adding iadademstat to standard ASTX727 therapy improves outcomes for people with advanced myeloproliferative neoplasms (MPNs), a group of blood cancers. About 62 adults with accelerated or blast-phase MPNs will be randomly assigned to receive ASTX727 alon…

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This study tests a new drug, givinostat, against the current standard treatment hydroxyurea in 220 adults with a high-risk form of polycythemia vera, a blood cancer that increases red blood cells. The goal is to see if givinostat better controls blood counts and spleen size witho…

This study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who have already been taking the drug bomedemstat and are doing well on it. The goal is to collect more information on the drug's long-term safety and how well it continues to wo…

This study compares two newer blood thinners (apixaban and rivaroxaban) against daily low-dose aspirin to prevent dangerous blood clots in people with JAK2-positive myeloproliferative neoplasms (blood cancers like polycythemia vera and essential thrombocythemia). About 1,300 high…

This study follows 36 Italian adults with polycythemia vera, a blood cancer that causes too many red blood cells. All participants had a good response to the drug Ropeginterferon alfa-2b in an earlier trial and continue taking it. Researchers will check every 6 months whether the…

This study follows about 200 adults with polycythemia vera (a rare blood cancer) who do not have an enlarged spleen and are starting treatment with ropeginterferon alfa-2b. Researchers will track how well the drug controls symptoms and blood counts over three years in everyday me…

This study looks at whether N-Acetylcysteine (N-AC), a common supplement, can reduce symptoms like fatigue and pain in adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. About 27 participants with essential thrombocythemia, polycythemia vera, or myelo…

This study tests whether a curcumin supplement can reduce inflammation and improve symptoms in people with certain blood disorders, including CCUS, low-risk MDS, and MPNs. The trial will enroll 30 participants who will receive either curcumin or a placebo for 12 months. Researche…

This study tests whether the drug ruxolitinib can reduce troubling symptoms like fatigue and itching in people with low-risk essential thrombocythemia (ET) or polycythemia vera (PV). About 60 adults with significant symptom burden will take ruxolitinib and be monitored for improv…

This study looks at a type of immune cell called monocytes in people with certain blood cancers (myeloproliferative neoplasms). Researchers want to see if these cells have unique features that could help diagnose the disease more accurately. About 70 adults with polycythemia vera…

This study looks at people with a blood condition called essential thrombocythemia (ET) who later develop polycythemia vera (PV), a related disorder. Researchers want to find out what factors cause this change and whether these patients have different outcomes than those diagnose…

This study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…